Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Phio Pharmaceuticals Corp. | d74244dex991.htm |
| 8-K - FORM 8-K - Phio Pharmaceuticals Corp. | d74244d8k.htm |
 RXi
Pharmaceuticals NASDAQ: RXII
Panel: Platform Technologies and
Novel Therapeutics 15th Annual Biotech in Europe Forum for Global Partnering and Investment Conference September 29, 2015 RXi Pharmaceuticals NASDAQ: RXII Panel: Platform Technologies and Novel Therapeutics 15th Annual Biotech in Europe Forum for Global Partnering and Investment Conference September 29, 2015 ® Exhibit 99.2 |
 2 Property of RXi Pharmaceuticals Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests” and similar expressions are intended to identify forward-looking statements. These statements are based on RXi Pharmaceuticals Corporation’s (the “Company”) current beliefs and expectations. Such statements include, but are not limited to, statements about the future development of the Company’s products (including timing of clinical trials and related matters associated therewith), the expected timing of certain developmental milestones, the reporting of unblinded data, potential partnership opportunities, the Company’s competition and market opportunity and pro forma estimates. The inclusion of forward-looking statements should not be regarded as a representation by the Company that any of its plans will be achieved. Actual results may differ from those set forth in this presentation due to risks and uncertainties in the Company’s business, including those identified under “Risk Factors” in the Company’s most recently filed Quarterly Report on Form 10-Q and in other filings the Company periodically makes with the U.S Securities and Exchange Commission. The Company does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation. |
 3 Property of RXi Pharmaceuticals From Platform to Product Company Platforms build on creative new ideas that can be broadly applied in drug development Platform companies struggle because their value is determined by ultimate product success Result: Companies disappear or the value of their platform is not maximized (few disease areas only) Result: Fewer patients get the benefit from use of the innovation Result: Reduced shareholder value due
to
under-utilized
platform
How Patients have Suffered in the Transition |
 4 Property of RXi Pharmaceuticals Platform Technologies & Novel Therapeutics Challenge: Evolve from a Platform-based Company into a Product- based Company while preserving the total value and potential of the Company. Solution: Identify innovative ways to capitalize on portions of the platform outside the Company’s strategic core focus in order to broaden the development of and access to novel therapeutics for patients and physicians, while building shareholder value. |
 5 Property of RXi Pharmaceuticals Transition Platform to Product Company Maintain Optimum Use of Innovation Identify Strategic identification of the disease areas in which your company wants to compete and which allow for demonstration of proof of concept of the platform in the near term Select 1–3 product candidates from your platform for internal development in the selected disease areas Collaborate Form research partnerships where relevant for optimum delivery of the selected development candidates Maximize IP Create immediate shareholder value by maximizing platform IP as a venture investment tool in start-up biotech firms, similar to venture capital funds Partner Conventional business development effort with large companies; including R&D contracts or through conventional out-licensing efforts |
 6 Property of RXi Pharmaceuticals Example: RXi Pharmaceuticals Started as platform RNAi company Transformational self-delivering RNAi (sd-rxRNA ® ) platform Multiple potential disease area targets Core Focus: Dermatology & Ophthalmology selected for product development Collaborations ongoing with 3 formulation companies Invested in an oncology cell therapy company through IP license to RXi’s self-delivering platform Negotiating a similar approach in another therapeutic area Negotiating conventional business development arrangements with larger regional/global firms Transition from Platform to Product Company |
 7 Property of RXi Pharmaceuticals sd-rxRNA ® : RXi’s Proprietary Platform RXi’s unique sd-rxRNA platform allows for rapid identification of lead compounds
for multiple targets in different therapeutic areas
RXi’s Strategic Core Focus
Open for Partnering/Licensing
sd-rxRNA Platform Dermatology Scarring (fibrosis) Hyperpigmentation disorders Photo aging Ophthalmology Retinal scarring AMD, PVR Corneal scarring Local Delivery Arthritis Endometriosis Lung Fibrosis Chronic wounds Systemic & Cancer Liver fibrosis Kidney fibrosis Cancer Cell Therapy Exclusive license to platform for cell-based immunotherapies in cancer Other therapeutic areas for cell therapy still available |